Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice

CNS Neuroscience and Therapeutics

Volumn 19, Issue 11, 2013, Pages 871-881

  Shi, Jian Quan ^a   Wang, Bian Rong ^b   Tian, You Yong ^a   Xu, Jun ^c   Gao, Li ^c   Zhao, Shu Li ^a   Jiang, Teng ^a   Xie, Hong Guang ^a   Zhang, Ying Dong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Geriatric Hospital   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Behavior; Histone deacetylase inhibition; Levetiracetam; Neuropathology; Topiramate

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ETIRACETAM; GAMMA SECRETASE; HISTONE DEACETYLASE; PRESENILIN 1; TOPIRAMATE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; DRUG EFFECT; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NEUROPATHOLOGY; NONHUMAN; TRANSGENIC MOUSE; TREATMENT DURATION; UPREGULATION;

ALZHEIMER'S DISEASE; BEHAVIOR; HISTONE DEACETYLASE INHIBITION; LEVETIRACETAM; NEUROPATHOLOGY; TOPIRAMATE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTICONVULSANTS; BRAIN; CELL LINE, TUMOR; FRUCTOSE; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PIRACETAM; PRESENILIN-1;

EID: 84885945251     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12144     Document Type: Article

References (61)

1. Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335-2338.
2. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006;52:3-13.
3. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011;34:185-204.
4. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012;2:a006247.
5. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992;256:184-185.
6. Delrieu J, Ousset PJ, Caillaud C, et al. 'Clinical trials in Alzheimer's disease': Immunotherapy approaches. J Neurochem 2012;120(Suppl 1):186-193.
7. Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986;36:1226-1230.
8. Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology 1996;46:727-730.
9. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006;47:867-872.
10. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009;66:435-440.
11. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007;55:697-711.
12. Minkeviciene R, Rheims S, Dobszay MB, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 2009;29:3453-3462.
13. Vogt DL, Thomas D, Galvan V, et al. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging 2011;32:1725-1729.
14. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci 2011;14:750-756.
15. Bakker A, Krauss GL, Albert MS, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012;74:467-474.
16. Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008;205:2781-2789.
17. Hu JP, Xie JW, Wang CY, et al. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Res Bull 2011;85:194-200.
18. Eyal S, Yagen B, Sobol E, et al. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004;45:737-744.
19. Kudin AP, Debska-Vielhaber G, Vielhaber S, et al. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004;45:1478-1487.
20. Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: Clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev 2011;33:289-293.
21. Thöne J, Ellrichmann G, Faustmann PM, et al. Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis. Int Immunopharmacol 2012;14:9-12.
22. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004;13:159-170.
23. Malm T, Koistinaho J, Kanninen K. Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications. Int J Alzheimers Dis 2011;2011:517160.
24. Shi JQ, Shen W, Chen J, et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011;1368:239-247.
25. Rasband WS. ImageJ v1. Bethesda, Maryland: U. S. National Institutes of Health, 1997-2011. http://rsb.info.nih.gov/ij/.
26. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001;21:372-381.
27. Peleg S, Sananbenesi F, Zovoilis A, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010;328:753-756.
28. Gräff J, Rei D, Guan JS, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012;483:222-226.
29. Foley AG, Gannon S, Rombach-Mullan N, et al. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology 2012;63:750-760.
30. Liu XS, Chopp M, Kassis H, et al. Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience 2012;220:313-321.
31. Xuan A, Long D, Li J, et al. Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci 2012;90:463-468.
32. Zhang Z, Zhang ZY, Wu Y, et al. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 2012;221:140-150.
33. Lv J, Du C, Wei W, et al. The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem 2012;287:28656-28665.
34. Xiong N, Jia M, Chen C, et al. Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience 2011;199:292-302.
35. Ziyatdinova S, Gurevicius K, Kutchiashvili N, et al. Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res 2011;94:75-85.
36. Zhang XZ, Li XJ, Zhang HY. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res Bull 2010;81:3-6.
37. Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011;77:1263-1271.
38. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853-861.
39. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol 2012;11:792-802.
40. Liu Y, Barks JD, Xu G, et al. Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke 2004;35:1460-1465.
41. Kouzounias K, Kimiskidis VK, Siozos T, et al. Topiramate promotes neurological recovery in a new model of traumatic brain injury in rats. Neuroscience 2011;183:171-177.
42. Gensel JC, Tovar CA, Bresnahan JC, et al. Topiramate treatment is neuroprotective and reduces oligodendrocyte loss after cervical spinal cord injury. PLoS ONE 2012;7:e33519.
43. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001;10:287-293.
44. Gibbs JE, Walker MC, Cock HR. Levetiracetam: Antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006;47:469-478.
45. Sugata S, Hanaya R, Kumafuji K, et al. Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats. Brain Res Bull 2011;86:36-41.
46. Cai Z, Yan LJ, Li K, et al. Roles of AMP-activated protein kinase in Alzheimer's disease. Neuromolecular Med 2012;14:1-14.
47. Tschäpe JA, Hammerschmied C, Mühlig-Versen M, et al. The neurodegeneration mutant löchrig interferes with cholesterol homeostasis and Appl processing. EMBO J 2002;21:6367-6376.
48. Won JS, Im YB, Kim J, et al. Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. Biochem Biophys Res Commun 2010;399:487-491.
49. Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010;285:9100-9113.
50. Cai Z, Li B, Li K, et al. Down-regulation of amyloid-β through AMPK activation by inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 cells. J Alzheimers Dis 2012;29:89-98.
51. Vingtdeux V, Chandakkar P, Zhao H, et al. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J 2011;25:219-231.
52. Li L, Zhang X, Le W. Autophagy dysfunction in Alzheimer's disease. Neurodegener Dis 2010;7:265-271.
53. Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 2011;43:38-45.
54. Lai AY, McLaurin J. Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim Biophys Acta 2012;1822:1629-1637.
55. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
56. Banks WA, Kumar VB, Farr SA, et al. Impairments in brain-to-blood transport of amyloid-β and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-β protein precursor. J Alzheimers Dis 2011;23:599-605.
57. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004;35(11 Suppl 1):2628-2631.
58. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012;109:E2895-E2903.
59. Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: Randomized double-blind study. Neurology 2011;76:131-137.
60. Pandina GJ, Ness S, Polverejan E, et al. Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol 2010;42:187-195.
61. Frisch C, Kudin AP, Elger CE, et al. Amelioration of water maze performance deficits by topiramate applied during pilocarpine-induced status epilepticus is negatively dose-dependent. Epilepsy Res 2007;73:173-180.